Naloxone

Naloxone imageNaloxone is an opioid receptor antagonist that rapidly binds to opioid receptors, blocking heroin from activating them. An appropriate dose of naloxone acts in less than 2 minutes and completely eliminates all signs of opioid intoxication to reverse an opioid overdose.1 Between 1996 and 2014, naloxone reportedly reversed over 26,000 overdoses.2

 

Evzio and Narcan

Naloxone that can be used by nonmedical personnel has been shown to be cost-effective and save lives. 

In April 2014, the U.S. Food and Drug Administration (FDA) approved a naloxone hand-held auto-injector called Evzio®, which rapidly delivers a single dose of naloxone into the muscle or under the skin, buying time until medical assistance can arrive.3

Narcan® is an FDA approved prescription nasal spray that is used to stop a person from overdosing on opioids. It is a nasal form of naloxone.

Both Evzio® and Narcan® can be used on both adults and children and can be administered by first responders, family members, or caregivers.  

See: Step-by-step guide for using Narcan and doing rescue breathing on someone who has overdosed.

 

Finding Naloxone in Cleveland

pharmacy signThe opioid reversal drug is now available at pharmacies throughout the state without a prescription.

Get more information here.

NEW: Naloxone Toolkit

In September 2019, the Northeast Ohio Hospital Opioid Consortium launched a 'Naloxone Toolkit' containing a collection of naloxone-related resources for patients and families, providers, pharmacists, and social workers. Check it out on their website.

 


1Source:  National Institute of Drug Abuse (NIDA).  Research Report Series:  Heroin. November 2014, Bethesda, MD:  National Institute of Drug Abuse (NIDA).
2Source:
Centers for Disease Control and Prevention (CDC). Opioid Overdose Prevention Programs Providing Naloxone to Laypersons — United States, 2014.
3Source: National Institute of Drug Abuse (NIDA).  Research Report Series:  Heroin. November 2014, Bethesda, MD:  National Institute of Drug Abuse (NIDA).